Tumor‐Associated Fusobacterium nucleatum and Aggressive Architectural Features in Stage II Colorectal Cancer
Open Access
Abstract
Tumor budding (TB) and poorly differentiated clusters (PDCs) are histopathological indicators of invasive potential in colorectal cancer (CRC). Concurrently, Fusobacterium nucleatum ( F. nucleatum ) has emerged as a modulator of CRC progression. The relationship between intratumoral F. nucleatum and aggressive tumor architecture remains unknown. We evaluated 257 stage II primary CRCs. TB and PDC were assessed at the invasive front. Intratumoral F. nucleatum DNA was quantified from FFPE samples using droplet digital PCR. Associations between F. nucleatum load and molecular and clinicopathological features were analyzed. F. nucleatum was detected in 44.4% of tumors, with 19.8% classified as high bacterial load. Tumors with high F. nucleatum had a significantly higher frequency of intermediate‐ and high‐grade PDCs ( p = 0.047), with a specific enrichment for high‐grade PDCs ( p = 0.019). High F. nucleatum load was also associated with microsatellite instability (MSI‐H). No significant associations were observed between F. nucleatum presence or load and 10‐year overall, disease‐free, and cancer‐specific survival. A high F. nucleatum intratumoral burden was associated with aggressive tumor architecture characterized by PDC in stage II CRC. Nevertheless, no impact on long‐term clinical outcomes was observed, indicating that F. nucleatum had limited prognostic value.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2021/13861‐0)
This publication has 36 references indexed in Scilit:
- Host and microbiome lipid metabolism in colorectal cancer development and therapyTrends in Cancer, 2025
- Fusobacterium nucleatum Enrichment in Colorectal Tumor Tissue: Associations With Tumor Characteristics and Survival OutcomesGastro Hep Advances, 2025
- Tumour budding and poorly differentiated clusters in colon cancer – different manifestations of partial epithelial–mesenchymal transitionThe Journal of Pathology, 2022
- Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancerTrends in Microbiology, 2022
- Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) dataBritish Journal of Cancer, 2018
- Tumour budding in colorectal cancer: molecular rationale for clinical translationNature Reviews Cancer, 2018
- Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016Laboratory Investigation, 2017
- Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese populationJournal of Gastroenterology, 2017
- Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating AutophagyCell, 2017
- Systematic review and meta-analysis of the impact of tumour budding in colorectal cancerBritish Journal of Cancer, 2016